How to improve time-to-value using GxP computer systems
Explore the benefits of GxP computer systems to improve time-to-value so that companies can speed up the development and manufacture of life-saving drugs.
How to speed up regulatory submission in drug development
Digital workflows with an “audit-by-exception” approach help reduce errors and time to compile data, and therefore delays to market.
Improve your data management for quicker time to regulatory submission
Data silos and inconsistent data formats increase the chance of errors, which can have a significant impact on business operations. Digital workflows are the answer.
How cloud technologies help advance BioPharma manufacturing
Explore how cloud-based solutions can improve data visibility and transparency so that partners can enjoy equal access to data at all stages of the BioPharma lifecycle.
Tech transfer needs a new blueprint. Here’s why.
Discover how a shared data backbone in tech transfer can remove inefficiencies and inconsistencies found in a one-time transfer approach.
Proper data management is crucial for speeding up the process of discovering and developing drugs
Do you have a vision for clean, contextualized data? Is IT accountable to the bench in your lab? Are you willing to value even the most unassuming insights?
You need effective data management strategies early in the BioPharma lifecycle. Here’s why and how.
From ensuring data integrity to consolidating IP ownership, effective data management is key for BioPharma companies seeking a competitive edge.
Embrace a cloud-only approach to streamline your validation
A cloud-only approach provides many benefits, including streamlined validation, automated backups and upgrades, faster deployments and flexibility.
Speed up research discoveries with a digital data backbone
A digital data backbone can improve efficiency in the research process leading to earlier discoveries and lower costs. Discover how now.
How to avoid common pitfalls in the tech transfer process
Successful tech transfer can be a challenge, even for well-established biotechs. Here’s how to avoid common pitfalls at every stage.